Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,717 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Andersen S, et al. Kidney Int. 2000 Feb;57(2):601-6. doi: 10.1046/j.1523-1755.2000.00880.x. Kidney Int. 2000. PMID: 10652037 Clinical Trial.
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.
Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE, Navis G. Bos H, et al. Among authors: andersen s. Kidney Int Suppl. 2000 Apr;75:S32-7. Kidney Int Suppl. 2000. PMID: 10828759
Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
Andersen S, Schalkwijk CG, Stehouwer CD, Parving HH. Andersen S, et al. Diabetes Care. 2000 Jul;23(7):1031-2. doi: 10.2337/diacare.23.7.1031. Diabetes Care. 2000. PMID: 10895868 Clinical Trial. No abstract available.
Glomerular permselectivity in early stages of overt diabetic nephropathy.
Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Andersen S, et al. Kidney Int. 2000 Nov;58(5):2129-37. doi: 10.1111/j.1523-1755.2000.00386.x. Kidney Int. 2000. PMID: 11044234 Clinical Trial.
Evolving strategies for renoprotection: diabetic nephropathy.
Parving HH, Hovind P, Rossing K, Andersen S. Parving HH, et al. Among authors: andersen s. Curr Opin Nephrol Hypertens. 2001 Jul;10(4):515-22. doi: 10.1097/00041552-200107000-00006. Curr Opin Nephrol Hypertens. 2001. PMID: 11458033 Review.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Parving HH, et al. Among authors: andersen s. N Engl J Med. 2001 Sep 20;345(12):870-8. doi: 10.1056/NEJMoa011489. N Engl J Med. 2001. PMID: 11565519 Clinical Trial.
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Schjoedt KJ, et al. Among authors: andersen s. Diabetologia. 2004 Nov;47(11):1936-9. doi: 10.1007/s00125-004-1542-0. Epub 2004 Nov 17. Diabetologia. 2004. PMID: 15551047 Clinical Trial.
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH. Schjoedt KJ, et al. Among authors: andersen s. Scand J Clin Lab Invest. 2006;66(3):173-80. doi: 10.1080/00365510600548702. Scand J Clin Lab Invest. 2006. PMID: 16714246 Clinical Trial.
Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study.
Rosenlund S, Hansen TW, Andersen S, Rossing P. Rosenlund S, et al. Among authors: andersen s. Diabet Med. 2015 Nov;32(11):1445-52. doi: 10.1111/dme.12950. Epub 2015 Oct 6. Diabet Med. 2015. PMID: 26331364
Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark.
Andersen ST, Witte DR, Dalsgaard EM, Andersen H, Nawroth P, Fleming T, Jensen TM, Finnerup NB, Jensen TS, Lauritzen T, Feldman EL, Callaghan BC, Charles M. Andersen ST, et al. Among authors: andersen h. Diabetes Care. 2018 May;41(5):1068-1075. doi: 10.2337/dc17-2062. Epub 2018 Feb 27. Diabetes Care. 2018. PMID: 29487078
1,717 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page